• Generate Biomedicines highlighted GB-0895, a half-life extended anti-TSLP monoclonal antibody, with Phase 3 studies initiated for severe asthma.
• Program targets twice-yearly dosing via a single subcutaneous injection; femtomolar TSLP binding affinity of 106 fM, cited as 20x stronger than tezepelumab.
• Pipeline update flagged five computationally engineered clinical-stage or clinic-ready molecules; eight programs have reached candidate nomination.
• Cash balance totaled USD 221.5 million at year-end 2025; management framed a catalyst-heavy 12-24 month window led by GB-0895 readouts.
• Other near-term clinical starts include GB-4362 in metastatic urothelial cancer, GB-5267 in platinum-resistant ovarian cancer, both targeted for 1H26 initiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.